MEK inhibitors against MET-amplified non-small cell lung cancer

Masato Chiba, Yosuke Togashi, Shuta Tomida, Hiroshi Mizuuchi, Yu Nakamura, Eri Banno, Hidetoshi Hayashi, Masato Terashima, Marco A. De Velasco, Kazuko Sakai, Yoshihiko Fujita, Tetsuya Mitsudomi, Kazuto Nishio

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Several receptor tyrosine kinases (RTKs) including EGFR, ALK, and MET have been identified as therapeutic targets in non-small cell lung cancer (NSCLC). Among the downstream pathways of RTKs, the MAPK pathway is particularly important for cancer cell proliferation, differentiation, and survival. In this study, the effects of MEK inhibitors (trametinib and PD0325901) in several NSCLC cell lines with driver gene alterations, especially RTK genes, were tested in vitro using an MTT assay, and a wide range of sensitivities was found. In particular, all the EGFR-mutated cell lines were resistant to MEK inhibitors, whereas all the MET-amplified cell lines were sensitive. A bioinformatics technique and western blot analyses showed that the PI3K/AKT pathway is more activated in EGFRmutated NSCLC than in MET-amplified NSCLC, and a PI3K inhibitor enhanced the sensitivity to trametinib in the EGFR-mutated cell lines, suggesting that this pathway is associated with resistance to MEK inhibitors. Although the HCC827 cell line (EGFR mutation) was resistant to MEK inhibitors, the HCC827CNXR cell line, whose driver gene shifts from EGFR to MET, exhibited enhanced sensitivity to MEK inhibitors, indicating the biological importance of the MAPK pathway for MET-amplified NCSLC. Furthermore, a synergistic effect of crizotinib (a MET inhibitor) and trametinib was observed in MET-amplified NCLC cell lines. Our findings indicate that the MAPK pathway is biologically important for MET-amplified NSCLC and strongly encourage the development of combination therapy with a MET inhibitor and a MEK inhibitor against MET-amplified NSCLC.

Original languageEnglish
Pages (from-to)2236-2244
Number of pages9
JournalInternational Journal of Oncology
Volume49
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Non-Small Cell Lung Carcinoma
Cell Line
Receptor Protein-Tyrosine Kinases
Phosphatidylinositol 3-Kinases
erbB-1 Genes
Computational Biology
Genes
Cell Differentiation
Cell Survival
Western Blotting
Cell Proliferation
Mutation
Therapeutics
trametinib
Neoplasms

Keywords

  • MAPK pathway
  • MEK inhibitor
  • MET amplification
  • MET inhibitor
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chiba, M., Togashi, Y., Tomida, S., Mizuuchi, H., Nakamura, Y., Banno, E., ... Nishio, K. (2016). MEK inhibitors against MET-amplified non-small cell lung cancer. International Journal of Oncology, 49(6), 2236-2244. https://doi.org/10.3892/ijo.2016.3736

MEK inhibitors against MET-amplified non-small cell lung cancer. / Chiba, Masato; Togashi, Yosuke; Tomida, Shuta; Mizuuchi, Hiroshi; Nakamura, Yu; Banno, Eri; Hayashi, Hidetoshi; Terashima, Masato; De Velasco, Marco A.; Sakai, Kazuko; Fujita, Yoshihiko; Mitsudomi, Tetsuya; Nishio, Kazuto.

In: International Journal of Oncology, Vol. 49, No. 6, 01.12.2016, p. 2236-2244.

Research output: Contribution to journalReview article

Chiba, M, Togashi, Y, Tomida, S, Mizuuchi, H, Nakamura, Y, Banno, E, Hayashi, H, Terashima, M, De Velasco, MA, Sakai, K, Fujita, Y, Mitsudomi, T & Nishio, K 2016, 'MEK inhibitors against MET-amplified non-small cell lung cancer', International Journal of Oncology, vol. 49, no. 6, pp. 2236-2244. https://doi.org/10.3892/ijo.2016.3736
Chiba, Masato ; Togashi, Yosuke ; Tomida, Shuta ; Mizuuchi, Hiroshi ; Nakamura, Yu ; Banno, Eri ; Hayashi, Hidetoshi ; Terashima, Masato ; De Velasco, Marco A. ; Sakai, Kazuko ; Fujita, Yoshihiko ; Mitsudomi, Tetsuya ; Nishio, Kazuto. / MEK inhibitors against MET-amplified non-small cell lung cancer. In: International Journal of Oncology. 2016 ; Vol. 49, No. 6. pp. 2236-2244.
@article{29f6282461be4ea38341738704aa0ca3,
title = "MEK inhibitors against MET-amplified non-small cell lung cancer",
abstract = "Several receptor tyrosine kinases (RTKs) including EGFR, ALK, and MET have been identified as therapeutic targets in non-small cell lung cancer (NSCLC). Among the downstream pathways of RTKs, the MAPK pathway is particularly important for cancer cell proliferation, differentiation, and survival. In this study, the effects of MEK inhibitors (trametinib and PD0325901) in several NSCLC cell lines with driver gene alterations, especially RTK genes, were tested in vitro using an MTT assay, and a wide range of sensitivities was found. In particular, all the EGFR-mutated cell lines were resistant to MEK inhibitors, whereas all the MET-amplified cell lines were sensitive. A bioinformatics technique and western blot analyses showed that the PI3K/AKT pathway is more activated in EGFRmutated NSCLC than in MET-amplified NSCLC, and a PI3K inhibitor enhanced the sensitivity to trametinib in the EGFR-mutated cell lines, suggesting that this pathway is associated with resistance to MEK inhibitors. Although the HCC827 cell line (EGFR mutation) was resistant to MEK inhibitors, the HCC827CNXR cell line, whose driver gene shifts from EGFR to MET, exhibited enhanced sensitivity to MEK inhibitors, indicating the biological importance of the MAPK pathway for MET-amplified NCSLC. Furthermore, a synergistic effect of crizotinib (a MET inhibitor) and trametinib was observed in MET-amplified NCLC cell lines. Our findings indicate that the MAPK pathway is biologically important for MET-amplified NSCLC and strongly encourage the development of combination therapy with a MET inhibitor and a MEK inhibitor against MET-amplified NSCLC.",
keywords = "MAPK pathway, MEK inhibitor, MET amplification, MET inhibitor, Non-small cell lung cancer",
author = "Masato Chiba and Yosuke Togashi and Shuta Tomida and Hiroshi Mizuuchi and Yu Nakamura and Eri Banno and Hidetoshi Hayashi and Masato Terashima and {De Velasco}, {Marco A.} and Kazuko Sakai and Yoshihiko Fujita and Tetsuya Mitsudomi and Kazuto Nishio",
year = "2016",
month = "12",
day = "1",
doi = "10.3892/ijo.2016.3736",
language = "English",
volume = "49",
pages = "2236--2244",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - MEK inhibitors against MET-amplified non-small cell lung cancer

AU - Chiba, Masato

AU - Togashi, Yosuke

AU - Tomida, Shuta

AU - Mizuuchi, Hiroshi

AU - Nakamura, Yu

AU - Banno, Eri

AU - Hayashi, Hidetoshi

AU - Terashima, Masato

AU - De Velasco, Marco A.

AU - Sakai, Kazuko

AU - Fujita, Yoshihiko

AU - Mitsudomi, Tetsuya

AU - Nishio, Kazuto

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Several receptor tyrosine kinases (RTKs) including EGFR, ALK, and MET have been identified as therapeutic targets in non-small cell lung cancer (NSCLC). Among the downstream pathways of RTKs, the MAPK pathway is particularly important for cancer cell proliferation, differentiation, and survival. In this study, the effects of MEK inhibitors (trametinib and PD0325901) in several NSCLC cell lines with driver gene alterations, especially RTK genes, were tested in vitro using an MTT assay, and a wide range of sensitivities was found. In particular, all the EGFR-mutated cell lines were resistant to MEK inhibitors, whereas all the MET-amplified cell lines were sensitive. A bioinformatics technique and western blot analyses showed that the PI3K/AKT pathway is more activated in EGFRmutated NSCLC than in MET-amplified NSCLC, and a PI3K inhibitor enhanced the sensitivity to trametinib in the EGFR-mutated cell lines, suggesting that this pathway is associated with resistance to MEK inhibitors. Although the HCC827 cell line (EGFR mutation) was resistant to MEK inhibitors, the HCC827CNXR cell line, whose driver gene shifts from EGFR to MET, exhibited enhanced sensitivity to MEK inhibitors, indicating the biological importance of the MAPK pathway for MET-amplified NCSLC. Furthermore, a synergistic effect of crizotinib (a MET inhibitor) and trametinib was observed in MET-amplified NCLC cell lines. Our findings indicate that the MAPK pathway is biologically important for MET-amplified NSCLC and strongly encourage the development of combination therapy with a MET inhibitor and a MEK inhibitor against MET-amplified NSCLC.

AB - Several receptor tyrosine kinases (RTKs) including EGFR, ALK, and MET have been identified as therapeutic targets in non-small cell lung cancer (NSCLC). Among the downstream pathways of RTKs, the MAPK pathway is particularly important for cancer cell proliferation, differentiation, and survival. In this study, the effects of MEK inhibitors (trametinib and PD0325901) in several NSCLC cell lines with driver gene alterations, especially RTK genes, were tested in vitro using an MTT assay, and a wide range of sensitivities was found. In particular, all the EGFR-mutated cell lines were resistant to MEK inhibitors, whereas all the MET-amplified cell lines were sensitive. A bioinformatics technique and western blot analyses showed that the PI3K/AKT pathway is more activated in EGFRmutated NSCLC than in MET-amplified NSCLC, and a PI3K inhibitor enhanced the sensitivity to trametinib in the EGFR-mutated cell lines, suggesting that this pathway is associated with resistance to MEK inhibitors. Although the HCC827 cell line (EGFR mutation) was resistant to MEK inhibitors, the HCC827CNXR cell line, whose driver gene shifts from EGFR to MET, exhibited enhanced sensitivity to MEK inhibitors, indicating the biological importance of the MAPK pathway for MET-amplified NCSLC. Furthermore, a synergistic effect of crizotinib (a MET inhibitor) and trametinib was observed in MET-amplified NCLC cell lines. Our findings indicate that the MAPK pathway is biologically important for MET-amplified NSCLC and strongly encourage the development of combination therapy with a MET inhibitor and a MEK inhibitor against MET-amplified NSCLC.

KW - MAPK pathway

KW - MEK inhibitor

KW - MET amplification

KW - MET inhibitor

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84996486082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996486082&partnerID=8YFLogxK

U2 - 10.3892/ijo.2016.3736

DO - 10.3892/ijo.2016.3736

M3 - Review article

C2 - 27748834

AN - SCOPUS:84996486082

VL - 49

SP - 2236

EP - 2244

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -